ZA965666B - Preparations and methods for the treatment of t cell mediated diseases - Google Patents

Preparations and methods for the treatment of t cell mediated diseases

Info

Publication number
ZA965666B
ZA965666B ZA965666A ZA965666A ZA965666B ZA 965666 B ZA965666 B ZA 965666B ZA 965666 A ZA965666 A ZA 965666A ZA 965666 A ZA965666 A ZA 965666A ZA 965666 B ZA965666 B ZA 965666B
Authority
ZA
South Africa
Prior art keywords
cell mediated
preparations
treatment
mediated diseases
methods
Prior art date
Application number
ZA965666A
Other languages
English (en)
Inventor
Irun R Cohen
Dana Elias
Meir Shinitzky
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of ZA965666B publication Critical patent/ZA965666B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
ZA965666A 1995-07-05 1996-07-04 Preparations and methods for the treatment of t cell mediated diseases ZA965666B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases

Publications (1)

Publication Number Publication Date
ZA965666B true ZA965666B (en) 1997-01-27

Family

ID=11067727

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA965666A ZA965666B (en) 1995-07-05 1996-07-04 Preparations and methods for the treatment of t cell mediated diseases

Country Status (22)

Country Link
EP (1) EP0837672B9 (xx)
JP (2) JP4357595B2 (xx)
KR (1) KR100435040B1 (xx)
CN (1) CN1102382C (xx)
AT (1) ATE254451T1 (xx)
AU (1) AU714970B2 (xx)
CA (1) CA2226013C (xx)
CZ (1) CZ298A3 (xx)
DE (1) DE69630787T2 (xx)
DK (1) DK0837672T3 (xx)
ES (1) ES2211963T3 (xx)
HR (1) HRP960315A2 (xx)
HU (1) HU223081B1 (xx)
IL (2) IL114458A0 (xx)
MX (1) MX9800190A (xx)
NO (1) NO320363B1 (xx)
PT (1) PT837672E (xx)
SI (1) SI0837672T1 (xx)
UY (1) UY24275A1 (xx)
WO (1) WO1997002016A1 (xx)
YU (1) YU40796A (xx)
ZA (1) ZA965666B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) * 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
EP2301566B1 (en) 2002-05-21 2013-07-03 Irun R. Cohen DNA vaccines encoding heat shock proteins
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (en) * 2003-05-12 2004-11-18 Peptor Ltd. Compositions and methods for modulation of specific epitopes of hsp60
WO2005048914A2 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
WO2006072946A2 (en) 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
JP2009508517A (ja) 2005-09-22 2009-03-05 コーエン，イルン，アール Ｔ細胞受容体定常ドメインの免疫原性断片及びそれに由来するペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients

Also Published As

Publication number Publication date
JP4357595B2 (ja) 2009-11-04
EP0837672A4 (en) 1999-01-27
AU714970B2 (en) 2000-01-13
CN1102382C (zh) 2003-03-05
KR19990028738A (ko) 1999-04-15
EP0837672B1 (en) 2003-11-19
SI0837672T1 (en) 2004-04-30
NO980013D0 (no) 1998-01-02
ES2211963T3 (es) 2004-07-16
YU40796A (sh) 1998-11-05
HUP9802834A3 (en) 2001-08-28
CN1193907A (zh) 1998-09-23
MX9800190A (es) 1998-04-30
JP2009242412A (ja) 2009-10-22
CA2226013A1 (en) 1997-01-23
EP0837672A1 (en) 1998-04-29
IL114458A0 (en) 1995-11-27
HRP960315A2 (en) 1998-02-28
AU6484496A (en) 1997-02-05
EP0837672B9 (en) 2005-06-15
HU223081B1 (hu) 2004-03-29
NO980013L (no) 1998-02-19
IL122755A (en) 2004-07-25
CZ298A3 (cs) 1998-06-17
IL122755A0 (en) 1998-08-16
CA2226013C (en) 2012-09-18
UY24275A1 (es) 2000-12-29
JPH11508899A (ja) 1999-08-03
ATE254451T1 (de) 2003-12-15
DK0837672T3 (da) 2004-03-22
KR100435040B1 (ko) 2004-08-18
HUP9802834A2 (hu) 1999-03-29
NO320363B1 (no) 2005-11-28
DE69630787D1 (de) 2003-12-24
WO1997002016A1 (en) 1997-01-23
PT837672E (pt) 2004-03-31
DE69630787T2 (de) 2004-10-07

Similar Documents

Publication Publication Date Title
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
FR14C0051I2 (fr) Dialkylfumarates pour le traitement de maladies autoimmunes
AU3844297A (en) Treatment of autoimmune diseases
ATE206041T1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
SI1270595T1 (sl) Protitelo proti CCR4 in njegov fragment
ES2153665T3 (es) Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.
ZA965666B (en) Preparations and methods for the treatment of t cell mediated diseases
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
PT879056E (pt) Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
PT952772E (pt) Processos de utilizacao de fagocitos mononuclears para promover a regeneracao axonal
IT1319275B1 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo.
PT782630E (pt) Gene da doenca poliquistica do rim
Ito et al. CCR5 is a novel target for the treatment of experimental alopecia areata
HUP9901077A2 (hu) Gyógyszerkészítmény T-sejtek által közvetített gyulladásos bőrbetegségek ellen
AU6953296A (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
Wrigley et al. Normal cerebral function with bilateral carotid occlusion.
EP1052285A3 (en) Method of inducing an antigen-specific anticytotoxic cell
UA28518A (uk) Спосіб визначення алергену у хворих на лікарську хворобу
Dorr Modulatory effects of cimetidine on the bovine immune system: Cell-mediated immunity, suppressor cell function and immunoglobulin-E production.
Harrington COMPARING THE RELIGIOUS BELIEF AND PRACTICE AND PERCEIVED FAMILY ENVIRONMENTS OF METROPOLITAN BOSTON CATHOLIC PAROCHIAL SCHOOL EIGHTH-GRADERS: TOWARD A RELIGIOUS-PSYCHOLOGICAL INTERFACE.
WO2001038394A3 (en) Polypetptides and methods for thymic vaccination
ES2183376T3 (es) Uso de lbp para el tratamiento de la septicemia.
UA6640A (uk) Спосіб прогнозування загострення супутнього захворювання при активізації основної патології